US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Principal U.S. Small-Cap Multi-Factor ETF

53.09

+0.14000.26%

Post-market: 53.02-0.0700-0.13%16:04 EDT

Volume:63.76K

Turnover:3.38M

Market Cap:750.69M

PE:58.99

High:53.48

Open:53.22

Low:52.64

Close:52.95

Loading ...

Overview Company News Filings

GE2025: Why Singapore's high-flying bureaucrats are recruited into politics

Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC

LIVMARLI Now Approved in Japan for ALGS and PFIC

Is EZCORP Inc. (EZPW) the Best Small-Cap Value Stock to Buy Now?

NuEnergy Gas Shifts Focus to Advanced CBM Projects with Muara Enim 2 PSC Relinquishment

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Commentary: Trump’s mass firings and civil service shake-up - could it happen in Singapore?

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Reports 2024 Financial Results and Advances PSC Treatment

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

FPL files details of new rate plan designed to power growing state with unmatched combination of high reliability and low bills

AGO Raids Pertamina Patra Niaga's Tanjung Gurem Fuel Terminal

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Chemomab Aligns with FDA on Phase 3 Trial Path for PSC Drug

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

National Bank of Umm Al-Qaiwain (PSC) And 2 Other Promising Penny Stocks For Savvy Investors

Simply Wall St.

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PSC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","market":"US","secType":"STK","nameCN":"Principal U.S. Small-Cap Multi-Factor ETF","latestPrice":53.09,"timestamp":1751054400000,"preClose":52.95,"halted":0,"volume":63763,"hourTrading":{"tag":"盘后","latestPrice":53.02,"preClose":53.09,"latestTime":"16:04 EDT","volume":4,"amount":212.36,"timestamp":1751054653618},"delay":0,"floatShares":14140001,"shares":14140001,"eps":0.9,"marketStatus":"Market Closed","change":0.14,"latestTime":"06-27 16:00:00 EDT","open":53.22,"high":53.48,"low":52.64,"amount":3382275.75,"amplitude":0.015864,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.9,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.95,"sharesOutstanding":14140001,"nav":52.894132,"aum":749891717.47,"dividendRate":0.007534,"bidAskSpread":0.001786,"postHourTrading":{"tag":"盘后","latestPrice":53.02,"preClose":53.09,"latestTime":"16:04 EDT","volume":4,"amount":212.36,"timestamp":1751054653618},"volumeRatio":0.7598449872944438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","floatShares":14140001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7598449872944438,"shares":14140001,"dividePrice":0.4,"high":53.48,"amplitude":0.015864,"preClose":52.95,"low":52.64,"week52Low":42.36,"pbRate":"--","week52High":57.24,"institutionHeld":0,"latestPrice":53.09,"eps":0.9,"divideRate":0.007534,"volume":63763,"delay":0,"ttmEps":0.9,"open":53.22,"prevYearClose":51.27,"prevWeekClose":51.51,"prevMonthClose":51.12,"prevQuarterClose":48.5596,"fiveDayClose":51.51,"twentyDayClose":51.22,"sixtyDayClose":48.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522526805","title":"GE2025: Why Singapore's high-flying bureaucrats are recruited into politics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522526805","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522526805?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:00","pubTimestamp":1743112800,"startTime":"0","endTime":"0","summary":"In recent weeks, top ministry officials have resigned, fuelling speculation they could be fielded as potential candidates for the ruling People's Action Party in the 2025 General Election.","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s--P9fINhag--/c_crop,h_900,w_1600,x_0,y_0/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/civil-servants-politics-hero.png?itok=zaq0mQYL","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--P9fINhag--/c_crop,h_900,w_1600,x_0,y_0/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/civil-servants-politics-hero.png?itok=zaq0mQYL"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/ge2025-civil-servants-public-service-politics-candidates-pap-5015676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU1064131342.USD","LU1261432733.SGD","LU1366333091.USD","LU0354030511.USD","LU0943347566.SGD","LU1551013342.USD","LU1988902786.USD","BK4501","GE","LU2756315318.SGD","LU0820561818.USD","LU0820562030.AUD","LU1093756325.SGD","LU2543165471.USD","LU2264538146.SGD","LU0354030438.USD","DM0.SI","LU1551013425.SGD","BK6053","LU1093756168.USD","PSC","LU1280957306.USD","LU0640476718.USD","BK4206","BK4566","LU0820561909.HKD","BK4588","BK4187","LU0149725797.USD","MP","LU0157215616.USD","BK4585","LU0689472784.USD","LU2756315664.SGD","IE00BD6J9T35.USD","LU0868494617.USD","BK4543","BK4168"],"gpt_icon":0},{"id":"2522303719","title":"Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303719","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303719?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:57","pubTimestamp":1743080251,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics ( ($CMMB) ) has shared an update. On March 27, 2025, Chemomab Therapeutics announced positive results from the Open Label Ext...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomabs-nebokitug-shows-promising-phase-2-results-for-psc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomabs-nebokitug-shows-promising-phase-2-results-for-psc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2522301581","title":"LIVMARLI Now Approved in Japan for ALGS and PFIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301581","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301581?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078600,"startTime":"0","endTime":"0","summary":"- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan. FOSTER CITY, Calif., March 27, 2025----Mirum Pharmaceuticals, Inc.  today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI  oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis  in Japan.\"We are thrilled to see LIVMARLI approved as the first and only medication available in Japan for patients living with pruritus related to ALGS and PFIC,\" said Chris Peetz, chief executive officer at Mirum. \"Takeda is a leading global pharmaceutical company with demonstrated success in the development and commercialization of medicines for rare diseases. Under Takeda’s leadership, we are confident that LIVMARLI could have a meaningful imp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/livmarli-now-approved-japan-algs-123000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRM","BSEP","ALGS","BK4139","BK4505","IBAT","BK4585","BK4079","BK4532","BK4520","PSC","FSV","X","BK4516","BK4006","BK4588"],"gpt_icon":0},{"id":"2521720769","title":"Is EZCORP Inc. (EZPW) the Best Small-Cap Value Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521720769","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521720769?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:15","pubTimestamp":1742822122,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Small-Cap Value Stocks to Buy Now. In this article, we are going to take a look at where EZCORP Inc.  stands against other best small-cap value stocks to buy now.Earlier on February 24, Robert Teeter of Silvercrest Asset Management shared his perspective on small-cap stocks and highlighted their link to economic conditions and sensitivity to financing activity. He noted that the Trump trade initially boosted small caps due to expectations of economic acceleration and lower interest rates, both of which are favorable for these companies. However, policy uncertainty and weaker-than-expected economic data have delayed their rally. Teeter believes that small caps will come into their own later in the year, but for now, they are facing a choppy market with significant rotation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ezcorp-inc-ezpw-best-small-131522645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","SQQQ","TSYW.SI","EZPW","PSQ","MNQmain","QLD","NVIW.SI","QID","BK4166","USAW.SI","USJW.SI","PSC","NQmain",".IXIC"],"gpt_icon":1},{"id":"2518763253","title":"NuEnergy Gas Shifts Focus to Advanced CBM Projects with Muara Enim 2 PSC Relinquishment","url":"https://stock-news.laohu8.com/highlight/detail?id=2518763253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518763253?lang=en_us&edition=fundamental","pubTime":"2025-03-11 13:19","pubTimestamp":1741670384,"startTime":"0","endTime":"0","summary":"NuEnergy Gas Limited ( ($AU:NGY) ) has shared an announcement. NuEnergy Gas Limited has announced the relinquishment of its 30% interest in the Mua...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuenergy-gas-shifts-focus-to-advanced-cbm-projects-with-muara-enim-2-psc-relinquishment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuenergy-gas-shifts-focus-to-advanced-cbm-projects-with-muara-enim-2-psc-relinquishment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B66KJ199.SGD","IE00B19Z4B17.USD","AEIS","IE00B7SZL793.SGD","BK4157","PSC","IE0031619046.USD"],"gpt_icon":0},{"id":"2518367087","title":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518367087","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518367087?lang=en_us&edition=fundamental","pubTime":"2025-03-11 08:00","pubTimestamp":1741651200,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., March 11, 2025----Mirum Pharmaceuticals, Inc.  today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units  to five new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635.Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI  oral solution, CHOLBAM  capsules, and CTEXLI  tablets.Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-inducement-grants-000000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","MNQmain","MIRM","LU2210149790.SGD","QLD","IE00B64PRP62.GBP","BK4112","TSYW.SI","NQmain","BK4585","BK4006","PSC","IE00BGHQF748.EUR","X","PSQ","BK4516","LU2210150020.SGD","IE00B3QW5Z07.USD","QID","BK4139","BK4520","NDAQ","IE00BKPKM429.USD","NVIW.SI","SQQQ",".IXIC","BK4588","LU2095319765.USD","USJW.SI","USAW.SI"],"gpt_icon":1},{"id":"2518215735","title":"Commentary: Trump’s mass firings and civil service shake-up - could it happen in Singapore?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518215735","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518215735?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:00","pubTimestamp":1741644000,"startTime":"0","endTime":"0","summary":"While our context is very different, Singapore must strive to keep public sector growth sustainable, says SUSS’s Terence Ho.","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s--WfsuXLQ5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/07/istock-1950678152.jpg?itok=gMP_xS_R","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--WfsuXLQ5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/07/istock-1950678152.jpg?itok=gMP_xS_R"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/commentary/trump-musk-doge-federal-job-cuts-government-employees-departments-closed-usaid-4984916","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2517154084","title":"New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154084","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154084?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Featuresof Systemic Sclerosis TEL AVIV, Israel, March  06, 2025  (GLOBE NEWSWIRE) -- Chemomab Therapeutics,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038138/0/en/New-Data-Presented-at-CORA-2025-Conference-Highlights-Clinical-Potential-of-Chemomab-s-Nebokitug-in-Systemic-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","BK4585","LU1559883803.SGD","ELF","LU1242518931.SGD","BK4183","LU0566484027.USD","PSC","LU0979878070.USD","BK4588","LU0053671581.USD"],"gpt_icon":0},{"id":"2516897636","title":"Chemomab Therapeutics Reports 2024 Financial Results and Advances PSC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516897636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516897636?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:29","pubTimestamp":1741008546,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Chemomab Therapeutics ( ($CMMB) ). Chemomab Therapeutics announced its year-end and fourth-quarter 2024 financi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-reports-2024-financial-results-and-advances-psc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-reports-2024-financial-results-and-advances-psc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC","BK4139","LENZ"],"gpt_icon":0},{"id":"2516635884","title":"Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635884","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635884?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035549/0/en/Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INN","ELF","BK4181","LU0566484027.USD","LU1242518857.USD","BK4585","LU0979878070.USD","LU0053671581.USD","LU1242518931.SGD","BK4218","LENZ","BK4139","PSC","LU1559883803.SGD","BK4588","BK4183"],"gpt_icon":0},{"id":"2514732240","title":"FPL files details of new rate plan designed to power growing state with unmatched combination of high reliability and low bills","url":"https://stock-news.laohu8.com/highlight/detail?id=2514732240","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514732240?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:45","pubTimestamp":1740750300,"startTime":"0","endTime":"0","summary":"JUNO BEACH, Fla., Feb. 28, 2025 /PRNewswire/ -- Florida Power & Light Company today submitted a comprehensive four-year request to the Florida Public Service Commission  to set new rates once its current base rate agreement concludes at the end of this year.The proposal, covering 2026 through 2029, would enable FPL to continue to deliver some of the nation's most reliable electricity, provide excellent customer service, diversify its generation resources to reduce fuel costs, and keep bills as low as possible.A word from FPL President and CEO Armando Pimentel: \"At FPL, we're focused on our customers every single day. The balanced plan we submitted to the PSC would enable FPL to continue to make smart investments in the grid and in new generation resources to benefit our customers and to power our fast-growing state. No other utility in the U.S. provides a better combination of reliability, resiliency and low bills than FPL.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fpl-files-details-rate-plan-134500596.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fpl-files-details-rate-plan-134500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXK94.USD","LU2498475776.HKD","LU1621767737.EUR","LU1988902786.USD","LU1621768115.EUR","LU2106854487.HKD","LU2275660780.HKD","LU0057025933.USD","NEE","LU1621768206.USD","LU2023250843.SGD","PSC","IE00BJTD4V19.USD","LU1084165304.USD","BK4581","LU0289960550.SGD","IE00BMG7P702.HKD","LU0175139822.USD","LU2298322129.HKD","LU2211814178.USD","IE00BMG7P587.USD","IE00B2PGVK34.USD","LU2023250504.SGD","LU2244417387.USD","IE00BMG7P694.USD","LU0289739343.SGD","LU0289961442.SGD","FPL","LU1929549753.HKD","LU2462611646.USD","LU0786609619.USD","BK4597","LU1064131342.USD","IE00BMG7P819.SGD","LU2637428348.USD","IE00BJTD4N35.SGD","BK4588","LU2264538146.SGD","BK4533","IE00BGHQF417.EUR","IE00BMG7P926.USD","LU1093756325.SGD","LU1366192091.USD","LU1939255532.USD","IE00B3CCJ633.GBP","LU2384288077.EUR","BK4606","LU0689626769.HKD","LU2048586759.USD","BK4566"],"gpt_icon":0},{"id":"2516537120","title":"AGO Raids Pertamina Patra Niaga's Tanjung Gurem Fuel Terminal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516537120","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516537120?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:51","pubTimestamp":1740739878,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -The Attorney General's Office  is conducting a raid at the Tanjung Gurem Fuel Terminal office in Grogol District, Cilegon, Banten. Based on Google Maps, the address corresponds to a fuel terminal owned by Pertamina Patra Niaga.“The raid has been underway since 10:30 a.m.,” said Harli Siregar, head of the AGO’s Legal Information Center, on February 28.The operation is part of an ongoing investigation into alleged corruption in the management of crude oil and refinery products at PT Pertamina, its sub-holdings, and Production Sharing Contract  contractors from 2018 to 2023.","market":"other","thumbnail":"https://statik.tempo.co/data/2025/02/27/id_1380677/1380677_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/02/27/id_1380677/1380677_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1981028/ago-raids-pertamina-patra-niagas-tanjung-gurem-fuel-terminal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4166","BK4107","PSC","PT","PSC.AU","BK7095","AGO"],"gpt_icon":0},{"id":"2514898508","title":"Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898508","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898508?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"- 2025 expected global net product sales of $420 million to $435 million. - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026. - CTEXLI  approved in the US for cerebrotendinous xanthomatosis. - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET. FOSTER CITY, Calif., February 26, 2025----Mirum Pharmaceuticals, Inc.  today reported financial results for the fourth quarter and year-end 2024 and provided a business update.\"2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,\" said Chris Peetz, chief executive officer of Mirum. \"We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of strong financial performance. On top of this, we are looking forward to multiple upcoming clinical and regulatory milestones, such as PSC where we’re expecting ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-fourth-quarter-210100952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["X","BK4079","PBC","BK4588","BK4585","BK4505","BK4532","PSC","BK4006","IBAT","BK4599","MIRM","BK4516","GGT","ALT","FSV","BK4139","BSEP","BK4520","LU1878469433.USD","FXS","ALGS"],"gpt_icon":1},{"id":"2513472184","title":"Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513472184","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513472184?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"CTEXLI is the first and only medication approved for the treatment of CTX in adults. CTEXLI granted U.S. FDA Orphan Drug exclusivity for the treatment of CTX. FOSTER CITY, Calif., February 24, 2025----Mirum Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has approved CTEXLI  tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis . CTEXLI is the first and only treatment approved for this rare, progressive and debilitating disease.In CTX, a deficiency of the bile acid chenodeoxycholic acid  leads to a buildup of bile alcohols which precedes a toxic accumulation of cholestanol. Cholestanol is the key driver of symptomatic burden and disease progression, including irreversible neurologic dysfunction. Results from the RESTORE study demonstrated that treatment with CTEXLI not only improved urine bile alcohol levels but also serum cholestanol levels. Additionally, a greater proportion of patients receiving placebo required blin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-ctexli-chenodiol-tablets-receives-133000189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","X","BK4139","PSC","BK4516","BK4520","BK4006","BK4585","MIRM"],"gpt_icon":0},{"id":"2512109194","title":"Chemomab Aligns with FDA on Phase 3 Trial Path for PSC Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2512109194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512109194?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:27","pubTimestamp":1739968072,"startTime":"0","endTime":"0","summary":"An update from Chemomab Therapeutics ( ($CMMB) ) is now available. On February 19, 2025, Chemomab Therapeutics announced the completion of its End-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomab-aligns-with-fda-on-phase-3-trial-path-for-psc-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomab-aligns-with-fda-on-phase-3-trial-path-for-psc-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2512051221","title":"Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512051221","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512051221?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:00","pubTimestamp":1739966400,"startTime":"0","endTime":"0","summary":"Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC. No Liver Biopsies or Additional Confirmatory Studies Required—Phase 3 Trial Endpoint Is Based onWell-Characterized Clinical Events Associated with PSC Disease Progression. Advancing Discussions with Potential Strategic Partners Post-FDA Feedback While Preparingfor Nebokitug Phase 3 Trial. Dr. Mor continued, “Importantly, key publications have shown that the reductions in PSC biomarkers in our nebokitug Phase 2 SPRING trial, especially the Enhanced Liver Fibrosis  and liver stiffness elastography measures, are associated with reductions in clinical events, increasing our confidence in the relevance of this approach for nebokitug and decreasing risk. We are looking forward to reporting topline data from the open label extension portion of the SPRING trial, which is prima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-completes-successful-end-phase-120000353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","BK4218","LU0053671581.USD","PSC","LU0566484027.USD","LU0979878070.USD","LU1242518857.USD","LU1559883803.SGD","LU1242518931.SGD","BK4207","BK4588","CM","CMMB","BK4139","BK4181","ELF","INN","BK4585"],"gpt_icon":0},{"id":"2510857623","title":"Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues","url":"https://stock-news.laohu8.com/highlight/detail?id=2510857623","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510857623?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:32","pubTimestamp":1739194324,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics, Inc.  stock is trading lower on Monday.On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis , a chronic lung disease that causes scarring and stiffening of the lung tissue.Patients currently enrolled in BEACON-IPF will remain in the trial.The move follows a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board.In May 2024, On Tuesday,Pliant Therapeutics announced topline data from a Phase 2a PET Imaging trial ofbexotegrast evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis  characterized by excessive collagendeposition in the lung.Last February, Pliant Therapeutics released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pliant-therapeutics-pauses-lead-product-133204055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PSC","BK4192","PET","SSI","BK4139","PLRX","BK4007"],"gpt_icon":0},{"id":"2508114087","title":"Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114087","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114087?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-participate-oppenheimer-35th-120000269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMMB","BK4137","HCSG","OPY","LENZ","PSC","BK4139","BK4127"],"gpt_icon":0},{"id":"2508165296","title":"National Bank of Umm Al-Qaiwain (PSC) And 2 Other Promising Penny Stocks For Savvy Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2508165296","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508165296?lang=en_us&edition=fundamental","pubTime":"2025-02-03 10:05","pubTimestamp":1738548322,"startTime":"0","endTime":"0","summary":"Global markets have recently experienced a mix of volatility and resilience, with U.S. stocks facing pressure from AI competition fears and tariff risks, while European indices benefited from strong earnings and interest rate cuts. In this context, investors may find value in exploring smaller or newer companies that offer growth potential at lower price points. Penny stocks, despite their somewhat outdated name, can still present compelling opportunities when backed by solid financials and strong fundamentals.Click here to see the full list of 5,711 stocks from our Penny Stocks screener.Overview: National Bank of Umm Al-Qaiwain  provides retail and corporate banking services in the United Arab Emirates, with a market capitalization of AED4.60 billion.Operations: The bank's revenue is primarily derived from Treasury and Investments, contributing AED418.58 million, followed by Retail and Corporate Banking with AED192.74 million.Click here to discover the nuances of National Bank of Umm ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_sg","url":"https://finance.yahoo.com/news/national-bank-umm-al-qaiwain-020522346.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/national-bank-umm-al-qaiwain-020522346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_sg","symbols":["NBHC","H22.SI","BK4211","BK6065","ISBC","BK6517","PSC"],"gpt_icon":0},{"id":"2505564488","title":"Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2505564488","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505564488?lang=en_us&edition=fundamental","pubTime":"2025-01-24 20:00","pubTimestamp":1737720000,"startTime":"0","endTime":"0","summary":"Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1  and Cohort 2  of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET. Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response. The five other patients in Cohorts 1 and 2 who previously experienced stable disease remain in stable disease. Two patients in Cohort 1 and seven patients in Cohort 2 received [212Pb]VMT-α-NET treatment prior to Cohort 2 being reopened in August 2024. These patients were enrolled for dose limiting toxicities observations. Initial results as of a data cut-off date of October 31, 2024 were previously presented at the 2024 North American Neuroendocrine Tumor Society  Multidis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/perspective-therapeutics-continues-pursue-dose-120000650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMC","BK4560","RPT","BK4585","BK4080","BK4231","BK4548","BK4554","BK4144","LU2286300806.USD","NET","PSC","BK4139","TAT","BK4588","BK4116","BK4110","CATX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSC\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"PSC","amount":0.110318,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-03"},{"date":"2024-12-27","symbol":"PSC","amount":0.07952,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2024-12-31"},{"date":"2024-10-01","symbol":"PSC","amount":0.1071,"announcedDate":"2024-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-01","defaultRemindTime":1727789400000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-10-01","currency":"USD","dateTimestamp":1727755200000,"payDate":"2024-10-03"},{"date":"2024-07-01","symbol":"PSC","amount":0.09909,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-01","name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-07-01","currency":"USD","dateTimestamp":1719806400000,"payDate":"2024-07-03"},{"date":"2024-04-01","symbol":"PSC","amount":0.096411,"announcedDate":"2024-03-28","type":"dividend","market":"US","newRecordDate":"2024-04-02","defaultRemindTime":1711978200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","recordDate":"2024-04-04","payableDate":"2024-04-02","currency":"USD","dateTimestamp":1711944000000,"payDate":"2024-04-04"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSC\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.0954808,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.073752,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.078723,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-05","value":0.053592,"currency":"USD"},{"executeDate":"2018-04-02","recordDate":"2018-04-03","paymentDate":"2018-04-05","value":0.083439,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSC\",market:\"US\",delay:false,,,undefined,":{}}}